PMC:7536954 / 4080-4291 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T54","span":{"begin":118,"end":120},"obj":"Disease"}],"attributes":[{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":37,"end":43},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T26","span":{"begin":55,"end":60},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T36","span":{"begin":55,"end":60},"obj":"Chemical"},{"id":"T37","span":{"begin":118,"end":120},"obj":"Chemical"}],"attributes":[{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}

{"project":"LitCovid-PubTator","denotations":[{"id":"167","span":{"begin":121,"end":129},"obj":"Species"},{"id":"171","span":{"begin":8,"end":19},"obj":"Chemical"},{"id":"172","span":{"begin":163,"end":174},"obj":"Chemical"},{"id":"173","span":{"begin":200,"end":210},"obj":"Chemical"}],"attributes":[{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Tax:9606"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"MESH:C555450"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"MESH:C555450"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"MESH:D000068879"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T42","span":{"begin":118,"end":120},"obj":"Phenotype"}],"attributes":[{"id":"A42","pred":"hp_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/HP_0040154"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}

{"project":"LitCovid-sentences","denotations":[{"id":"T38","span":{"begin":0,"end":211},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab."}